Physician profile
Arshad Iqbal
NPI 1174564983
$21,161.74
in general payments reported to CMS, 2019-2025
25 companies · $452 in 2025
The $452 reported for 2025 was less than what a typical Neurology (Psychiatry & Neurology) provider received nationally (typical 2025 total: $454).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $26.06 · 2020: $10K · 2021: $10K · 2022: $104 · 2023: $122 · 2024: $191 · 2025: $452.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $732 · Education: $33.12.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $731.55 |
| Education | $33.12 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic Vascular, INC. | $10,000.00 | 2020 | |
| Medtronic, INC. | $10,000.00 | 2021 | |
| Eisai INC. | $140.52 | 2022-2023 | |
| Csl Behring | $125.00 | 2020 | |
| Neurelis, INC. | $111.35 | 2022-2025 | Valtoco |
| Otsuka America Pharmaceutical, INC. | $90.08 | 2024-2025 | Rexulti |
| Abbvie INC. | $77.50 | 2021-2025 | |
| Emd Serono, INC. | $69.76 | 2022-2025 | |
| Teva Pharmaceuticals USA, INC. | $59.86 | 2024-2025 | Austedo Xr, Austedo Xr |
| Cycle Pharmaceuticals INC | $50.58 | 2025 | Bafiertam, Tascenso Odt |
| Novartis Pharmaceuticals Corporation | $49.10 | 2019-2021 | |
| Abbott Laboratories | $44.76 | 2021 | |
| Insightec,INC | $39.47 | 2025 | Exablate |
| Biogen, INC. | $36.28 | 2021-2024 | Skyclarys |
| Pfizer INC. | $36.05 | 2024-2025 |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Mdd US Operations, LLC | $35.00 | 2024 | Gocovri |
| Sk Life Science, INC. | $34.57 | 2025 | |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $33.12 | 2025 | Rexulti |
| Ucb, INC. | $25.48 | 2025 | Rystiggo |
| Livanova USA, INC. | $19.98 | 2021 | |
| Mallinckrodt Hospital Products INC. | $19.56 | 2025 | Acthar |
| Life Molecular Imaging LTD | $17.82 | 2024 | Neuraceq |
| Allergan, INC. | $16.75 | 2020 | |
| Noctrix Health, INC. | $16.66 | 2025 | Nidra |
| Biohaven Pharmaceuticals, INC. | $12.49 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Arshad Iqbal listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.